Leo Pharma Enters into a Sub-Licensing Agreement with Bausch Health to Develop and Commercialize Brodalumab for Moderate-to-Severe Psoriasis Outside Europe

Shots:

• Leo Pharma to get exclusive rights to develop & commercialize brodalumab in Australia, Brazil, Egypt, Mexico, Russia and Saudi Arabia for the treatment of moderate-to-severe psoriasis
• The sub-licensing agreement complements the ongoing licensing agreement b/w Leo & AstraZeneca to develop & commercialize brodalumab in Europe. Bausch Health has the rights to commercialize brodalumab through a licensing agreement with AstraZeneca outside Europe (Ex-Japan & other Asian countries) where Kyowa Kirin hold the rights
• Brodalumab (marketed as Kyntheum in the EU) is a mAb targeting IL-17 receptor A (IL17R) and has received EMA’s MAA in Jul’2017, currently indicated for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy

Click here to­ read full press release/ article | Ref: Business Wire | Image: PharmaStar